BIOLASE Receives FDA Clearance for the EPIC 10S Soft Tissue

New Post Public Reply Private Reply Replies (0) Message Board
testuser
BIOLASE Receives FDA Clearance for the EPIC 10S Soft Tissue Diode Laser for a Broad Spectrum of Medical Procedures

IRVINE, CA--(Marketwired - Apr 11, 2013) - BIOLASE, Inc. ( NASDAQ : BIOL ), the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration (FDA) has cleared the EPIC 10S™ soft tissue diode laser for use as a surgical instrument for over 80 different indications in 19 medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, orthopedics, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery (see Exhibit A for a detailed listing of medical markets and indications). The EPIC 10S is the surgical model of the recently released, next-generation dental EPIC 10™.

"We are extremely pleased to receive clearance for such a broad number of indications and procedures for our EPIC platform. The clearance for the EPIC 10S is based on the clearance we received in February 2013 for our older Diolase soft tissue diode laser and, needless to say, we are extremely happy to have received it so quickly," said Federico Pignatelli, Chairman and Chief Executive Officer. "This clearance gives us the ability to leverage our EPIC 10™ modular soft tissue diode laser platform and consumable business across a wide range of multi-billion dollar medical markets with appropriate strategic partners or in a direct mode. With the vast number of procedures now available for the EPIC, the opportunities for this new modular platform are tremendous."

BIOLASE's diode lasers are currently used in dentistry for a wide variety of surgical soft tissue procedures as an alternative to invasive and traumatic conventional devices, such as the high-speed drill, scalpel, or electrosurge. The 940nm laser wavelength of the EPIC 10 platform is better absorbed by hemoglobin (Hb) and oxyhemoglobin (HbO 2 ) than other diode laser wavelengths, so it cuts efficiently at low power and with considerably less heat and discomfort, making it an excellent alternative to conventional surgical devices. BIOLASE's EPIC 10 940nm wavelength diode laser uses disposable tips which help reduce the risk of infection and cross contamination and is also FDA cleared for tooth whitening and temporary pain relief.

"It is truly remarkable to see how our core technologies can impact so many other medical fields. Our 940nm diode lasers are excellent alternatives to conventional surgical devices and we have already begun performing clinical studies for a variety of these new applications and some of our early results have been extraordinary," said Fred Furry, Chief Operating Officer and Chief Financial Officer. "Our plan remains to focus on growing our core laser business in the dental market but we will also continue to expand the capabilities, applications, and indications for these core technologies in other medical markets, as well."

Exhibit A - Detailed Listing of Medical Markets and Indications for Use

Ear, Nose and Throat and Oral Surgery: Hemostasis, incision, excision, ablation, and vaporization of tissues from the ear, nose, throat and adjacent areas, including soft tissue in the oral cavity, such as:

  • Removal of benign lesions from ear, nose and throat
  • Excision and vaporization of vocal cord nodules and polyps
  • Incision and excision of carcinoma in-situ
  • Ablation and vaporization of hyperkeratosis
  • Laryngeal papillectomy
  • Excision and vaporization of herpes simplex I and II
  • Neck dissection

Arthroscopy: Hemostasis, incision, excision, vaporization, and ablation of joint tissues during arthroscopic surgery, such as:

  • Menisectomy
  • Syovectomy
  • Chondromalacia

Gastroenterology: Hemostasis, incision, excision, and vaporization of tissue in the upper and lower gastrointestinal tracts via endoscopy, such as:

  • Hemostasis of upper and lower GI bleeding
  • Excision and vaporization of colorectal carcinoma
  • Excision of polyps
  • Hemostasis of colonoscopy
  • Hemostasis of esophageal varices

Orthopedics:

  • Dissect and coagulate

General Surgery, Dermatology & Plastic Surgery, and Podiatry: Excision, ablation, vaporization, and photocoagulation of skin lesions, hemostasis, incision, excision, vaporization, ablation, and debulking of soft tissue, abdominal, rectal, skin, fat or muscle tissue, and dermabrasion, such as:

  • Matrixectomy
  • Excision of neuromas
  • Excision of periungual and subungual warts
  • Excision of plantar warts
  • Excision of Keloids
  • Excision of cutaneous lesions
  • Hemorrhoidectomy
  • Appendectomy
  • Debridement of decubitus ulcer
  • Hepatobiliary
  • Mastectomy
  • Dermabrasion
  • Vaporization & hemostasis of capillary hemangioma
  • Excision, vaporization & hemostasis of abdominal tumors
  • Excision, vaporization & hemostasis of rectal pathology
  • Pilonidal cystectomy
  • Herniorraphy
  • Adhesiolysis
  • Parathyroidectomy
  • Laparoscopic cholecystecomy
  • Thyroidectomy
  • Resection of organs

GI/GU: Excision, vaporization, and hemostasis of abdominal and rectal tissues, such as:

  • Hemorrhoidectomy
  • Excision, vaporization, and hemostasis of rectal pathology
  • Excision, vaporization, and hemostasis of abdominal tumors

Gynecology: Ablation, excision, hemostasis, and vaporization of tissue, such as:

  • Excision or vaporization of condylomata acuminata
  • Vaporization of CIN (cervical intraepithelial neoplasia)
  • Cervical conization
  • Menorrhagia
  • Ovarian cystectomy

Neurosurgery: Vaporization, coagulation, excision, incision, ablation and hemostasis of tissue, such as:

  • Hemostasis in conjunction with meningiomas
  • Percutaneous Disc Decompression (PLDD)

Ophthalmology:

  • Dacryocystorhinostomy transcanalicular
  • Open DCR
  • Tumor Excision
  • Blepharoplasty

Pulmonary Surgery: Hemostasis, vaporization, and excision of tissue, such as:

  • Tracheobronchial malignancy or stricture
  • Benign and malignant pulmonary obstruction

Cardiac Surgery:

  • Coagulation and hemostasis of cardiac tissue

Thoracic Surgery:

  • Thoracotomy
  • Pulmonary resection
  • Hemostasis
  • Pericardiectomy
  • Adhesiolysis
  • Coagulation of blebs and bullae

Urology: Hemostasis, vaporization, incision, coagulation, ablation, and excision of tissues, such as:

  • Vaporization of urethral tumors
  • Release of urethral stricture
  • Removal of bladder neck obstruction
  • Excision and vaporization of condyloma
  • Lesions of external genitalia
  • Circumcision
  • Vaporization of the prostate to treat benign prostate hyperplasia (BPH)

Dermatology/Aesthetics:

  • Photocoagulation of vascular & dermatological lesions of the face and extremities
  • Photocoagulation of telangiectasia, venulectasia of the legs and face
  • Treatment of reticular veins and branch varicosities
  • Pyrogenic granuloma, lymphangioma and lymphangiomatosis disease, angiofibromas
  • Superficial benign vascular lesions including Telangiectasias, hemangioma, Port wine stains, angiokeratoma, and benign epidermal pigment lesions as lentigines, epidermal nevi, spider nevi
  • Dermatological surgery: Condyloma acuminate, warts, small non-malignant skin tumors, small semi-malignant tumors as basaliomas, Bowe and Kaposi sarcoma, warty leucoplasty and ulcers debridement
  • Seborrheic keratosis
  • Mixoid cyst
  • Papillary varix
  • Acne treatment

Vascular Surgery:

  • Photocoagulation of vascular & dermatological lesions of the face and extremities
  • Photocoagulation of telangiectasia, veinulectasia of the legs and face
  • Treatment of reticular veins and branch varicosities

About BIOLASE, Inc. BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment ; products that are focused on technologies that advance the practice of dentistry and medicine . The Company's laser products incorporate over 340 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 22,000 lasers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com , Facebook at www.facebook.com/biolaseinc , Twitter at twitter.com/biolaseinc , and YouTube at www.youtube.com/biolasevideos .

For further information, please contact: Michael Porter Porter, LeVay & Rose, Inc. 212-564-4700

Investors-Hangout-Stock-Message-Boards-thumbnail-2015.png

test123 kjk
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xavier Ochsner Opens State-of-the-Art Medical School

Updated Category News Views 26

A New Era for Medical Education in New Orleans If you're familiar with New Orleans, you know it's a city defined by its vibrancy, culture, and resilience. Well, the Xavier Ochsner College of Medicine is adding to that narrative with the opening of their spanking new Center for Medical Education. It's a project that promises to shake things up in the best possible way for...

Continue Reading
Wastewater Treatment Market to Hit $99.56B by 2031

Updated Category News Views 86

The Changing Face of Wastewater Treatment Here's a whopper to chew on: the wastewater treatment services market ain't your grandfather's playground anymore. No sir, it's a fast-evolving arena aiming to swell to a whopping USD 99.56 billion by 2031. Now, how's that for growth? Mark my words, driven by stringent environmental regulations and thirst for clean water, this...

Continue Reading
Nuix Names Lori Cornmesser to Head Global Partnerships

Updated Category News Views 24

Nuix Shakes Things Up with New Leadership Nuix, a notable player in the investigative analytics and intelligence software space, just leveled up its game by bringing in Lori Cornmesser as the Global Vice President, Partner Ecosystems. This ain't your average hire. Cornmesser's been around the block—over 25 years, in fact—building and leading partner ecosystems...

Continue Reading
Reagan Institute's New Fellowship: Academic Game-Changer

Updated Category News Views 55

Aiming for an Academic Revival There’s hope on the horizon for academics wrestling to find their foothold among hallowed university halls. The Reagan Institute Society of Fellows is opening new doors for early career scholars. With heavyweight partners like Dartmouth and George Washington University joining forces, this is a solid lifeline amidst a sea of fading...

Continue Reading
Bit Digital Shifts Focus: Q3 2026 Sees Strategic Moves

Updated Category News Views 93

Bit Digital's Strategic Shakeup Ah, the digital gold rush is heating up again. Bit Digital, the outfit focused on Ethereum strategies and AI, dropped their financial results for Q3 2026. Picture a company at a strategic crossroads, shedding bitcoin mining baggage to grab hold of fresh opportunities in Ethereum staking and AI infrastructure. Bit Digital's earnings paint a...

Continue Reading
Flor de Caña's Green Strategy Wins 2026 Stevie Award

Updated Category News Views 19

Flor de Caña’s Environmental Triumph Seems like when folks think of premium rum, they might wanna start picturing not just smooth sips but a green commitment that runs deep. Flor de Caña has bagged a Stevie Award for their solid 'Net Zero Strategy of the Year.' This ain’t just any award; it's a nod from a respected crowd. A handshake from the business big shots who...

Continue Reading
IBM's Sports Tech Challenge Crowns AI Innovator LivXP

Updated Category News Views 57

Pioneering AI for Fan Engagement The big leagues of sports tech are buzzing, as IBM has just announced LivXP as the standout winner of their Sports Tech Startup Prize Challenge at the dynamic Web Summit Lisbon 2026. If there's one thing to remember, it's that this isn't just any accolade. This is a nod from IBM—an institution that's rubbed elbows with the giants of...

Continue Reading
Brigham Nurses Secure Contract, Avoid Historic Strike

Updated Category News Views 77

Victory for Brigham Nurses: Tentative Contract Reached Against a backdrop of looming unrest, over 4,000 registered nurses at Brigham and Women's Hospital have inked a tentative contract with Mass General Brigham. This isn't just a deal—it's relief to a near-crisis that would have kicked off with an open-ended strike. Standoff Averted at the Eleventh Hour How about...

Continue Reading
Poolwerx Expands in Florida: Matt Feldt's Bold Move

Updated Category News Views 31

A New Wave in Northeast Florida Bet you didn't expect to hear about pool care while sipping your morning coffee, but here we are. Poolwerx, the heavyweight champion in the pool service world, is pumping up its presence in the Northeast Florida landscape. Guess who’s the man behind this expansion? Matt Feldt, a Navy vet who’s traded in sonar for skimmers, has opened...

Continue Reading
Tax Strategies for Small Businesses Before Year-End

Updated Category News Views 44

Understanding the Importance of Year-Round Tax Planning Every small business owner dreads the tax season—like a thunderstorm on a picnic day. But here's a nugget from Paul Kersten, an Accounting and Tax whiz in Shawano, Wisconsin: don't wait until April to sort your taxes. By then, it's all receipts and regrets. Instead, consider tax planning as a year-long vigil. Why?...

Continue Reading

Top 5 Most Recently Viewed Articles

Fennec Pharmaceuticals Plans Public Offering for Growth

Updated Category News Views 185

Fennec Pharmaceuticals Moves Forward with Public Offering Fennec Pharmaceuticals Inc. (NASDAQ:FENC), a dynamic player in the pharmaceutical industry, has recently announced an exciting initiative to offer and sell its common shares through an underwritten public offering. This strategy not only reinforces its dedication to growth but also invites investors to partake in...

Continue Reading
Rent the Runway Strengthens Financial Position with New Deals

Updated Category News Views 260

Rent the Runway Revamps Financial Strategy Rent the Runway, Inc. (NASDAQ: RENT), a leader in apparel rentals and an innovator in the fashion subscription space, is excited to share the successful closing of its recent recapitalization transactions. This pivotal step aims to significantly improve the company's financial standing by reducing existing debt and extending its...

Continue Reading
Arcos Dorados Reports Mixed Q4 Results with Growth Insights

Updated Category News Views 124

Overview of Arcos Dorados Performance Recently, Arcos Dorados Holdings Inc. (NYSE: ARCO) shared its fourth-quarter performance, highlighting both challenges and victories in their latest earnings report. The company achieved an earnings per share (EPS) of 28 cents, surpassing analysts' expectations of 21 cents. Though this is a positive sign, the overall sales of $1.144...

Continue Reading
Celebrating Service: Fisher House Honors Military Community Leaders

Updated Category News Views 216

Empowering Military Families Through Innovation In a heartwarming display of support, the Fisher House Foundation, in partnership with the Military Times Foundation, has recently announced the winners of the prestigious Fisher Service Awards. These awards are designed to recognize and fund non-profit organizations dedicated to improving the lives of military service...

Continue Reading
City Office REIT Declares Quarterly Dividends for 2025

Updated Category News Views 144

City Office REIT Declares Quarterly Dividends City Office REIT, Inc. (NYSE: CIO) has made an important announcement regarding its dividends for shareholders. The Board of Directors has authorized a quarterly dividend of $0.10 per share of common stock and common unit of partnership interest for the second quarter of this financial year. In addition to the common stock...

Continue Reading